BANDAI NAMCO Entertainment and Crunchyroll Games Announce New Strategic Partnership
Leading interactive entertainment publisher and developer BANDAI NAMCO Entertainment Inc. (hereinafter referred to as BNE) and Crunchyroll Games, LLC (hereinafter referred to as Crunchyroll), today announced a strategic partnership with the goal of providing fans a rewarding and comprehensive experience with their favorite character IPs, through a variety of touchpoints, including animation, games and comics. Crunchyroll is the world’s largest destination for anime and manga, boasting a global community of more than 50 million registered users and over 2 million subscribers. This alliance combines BNE’s expertise on network content development and Crunchyroll’s direct connection to the anime community and robust platform services knowledge, providing a seamless anime and gaming entertainment experience for all.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190827005199/en/
Cross-Platform IP Experience (Graphic: Business Wire)
As a first step in this partnership, BNE’s browser and mobile game NARUTO X BORUTO NINJA TRIBES will be made available to Crunchyroll users in the U.S. this winter. NARUTO X BORUTO NINJA TRIBES is based on the popular NARUTO and BORUTO anime series, and brings together fan-favorite characters spanning multiple generations of both franchises for one-tap team-based battles. Crunchyroll fans who enjoy the anime series of the same IP on its platform can find and instantly play NARUTO X BORUTO NINJA TRIBES directly from Crunchyroll.com. BNE has plans to launch the game to other territories in the future.
“With Crunchyroll’s expansive global community and subscribers, this partnership was a strategic fit and critical step in expanding our entertainment business,” said Toru Konno, Director, BNE. “We have a corporate philosophy of creating ‘more fun for everyone’ and we are always striving to do that and look forward to seeing what we can build together with Crunchyroll in the coming years.”
“BANDAI NAMCO Entertainment is a global force that shares our goal of connecting the anime community to each other through beloved content,” said Joanne Waage, General Manager, Crunchyroll. “We’re looking forward to building on our partnership to offer even more interactive experiences to bring our fans together.”
For more information on NARUTO X BORUTO NINJA TRIBES , please visit the newly launched game website at https://en-narutoxboruto-tri.bn-ent.net/, or follow the official Facebook page at https://www.facebook.com/ninjatribes/.
About BANDAI NAMCO Entertainment Inc.
BANDAI NAMCO Entertainment Inc. delivers various products and services catering to a worldwide audience in areas such as network content, home video game software and life entertainment based on its IP (Intellectual Property) Axis. BNE gives shape to “a new type of fun” with amazing ideas and newer technology unavailable elsewhere. Furthermore, BNE makes ordinary everyday life more enjoyable and aims to realize “more fun for everyone” that allows customers throughout the world to keep smiling. For more information, please visit https://www.bandainamcoent.co.jp/english/.
About Crunchyroll Games
Crunchyroll Games is a Crunchyroll division focused on the publishing and distribution of anime-inspired interactive content, created to engage with the vibrant gaming enthusiasts across the Crunchyroll community. Crunchyroll is the world’s most popular anime brand, connecting a community of more than 50 million registered users and 2 million subscribers with 360-degree content experiences and the world’s largest collection of anime. Crunchyroll Games titles include “Bungo Stray Dogs: Tales of the Lost,” “Grand Summoners,” “RWBY: Crystal Match,” and the upcoming “Mob Psycho 100: Psychic Battle.” Crunchyroll Games are available across iOS and Android. For more on Crunchyroll Games, please visit crunchyrollgames.com.
*Information in the press release is current as of the announcement date. The contents are subject to change without notice. Please understand in advance.
©2002 MASASHI KISHIMOTO / 2017 BORUTO All Rights Reserved.
©BANDAI NAMCO Entertainment Inc.
All other trademarks are properties of their respective owners.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190827005199/en/
Contact information
fortyseven communications on behalf of BANDAI NAMCO Entertainment Inc.
Mitch Cavender
mitch@fortyseven.com
Crunchyroll
Bianca Doria
Bdoria@crunchyroll.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
BeOne Medicines Announces Positive Topline Results for Sonrotoclax in Relapsed or Refractory Mantle Cell Lymphoma (MCL)29.8.2025 13:00:00 EEST | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced positive topline results from a Phase 1/2 study (BGB-11417-201) of sonrotoclax, a next-generation and potentially best-in-class investigational BCL2 inhibitor, in adult patients with relapsed/refractory (R/R) mantle cell lymphoma (MCL), following treatment with a Bruton’s tyrosine kinase inhibitor (BTKi) and anti-CD20 therapy. BeOne plans to present the full data at an upcoming medical meeting. “For people with relapsed or refractory mantle cell lymphoma, the disease is aggressive, the treatment landscape fragmented, and the outcomes unacceptably poor. These topline results for sonrotoclax underscore its potential to deliver meaningful and durable responses and offer the first BCL2 inhibitor for patients with R/R MCL, if approved,” said Lai Wang, PhD, Global Head of R&D, BeOne Medicines. “These data add to the remarkable progress we’ve seen over the past five years in treating B-cel
Oulu2026 – European Capital of Culture: Oulu to Unveil Full European Capital of Culture 2026 Programme – Live Stream on 4 September 202529.8.2025 11:46:00 EEST | Press release
Hundreds of partners are creating a year in which Northern Finland becomes a new hub of culture. The programme will offer something for everyone: large-scale exhibitions, festivals across all genres, world premieres, performing arts, village celebrations, permanent artworks, sports, and community events across a vast region of 40 municipalities. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250829591577/en/ Oulu, with its 39 partner municipalities in Northern Finland, will step into the spotlight as European Capital of Culture 2026. The full programme will be officially launched on Thursday 4 September 2025 in Oulu, streamed live across Europe. The Oulu2026 programme is built around the theme of Cultural Climate Change, meaning a lasting enrichment of cultural life – connecting people through world-class experiences, creativity, and new ways of thinking. “2026 will be a transformative year – for our city, for Northern Finla
Nippon Sanso Holdings Group Unifies Global Brand Logo Launching the "NIPPON SANSO" Brand Worldwide29.8.2025 09:00:00 EEST | Press release
Nippon Sanso Holdings Corporation (President CEO: Toshihiko Hamada) will unify the brand logo for its industrial gas business globally and implement the change in stages. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250828253560/en/ Until now, our group has operated industrial gas businesses worldwide using the same symbol mark, while adapting to each region. To further enhance recognition and understanding of our group as a unified entity among a broad range of stakeholders, and to maximize corporate value and achieve sustainable growth, we have decided to unify the brand for our industrial gas businesses as "NIPPON SANSO" and standardize the brand logo globally. Moving forward, we will continue striving to be a trusted company for all stakeholders as a globally recognized brand. *Please note that Thermos Group, which operates the consumer household goods business within our group, will not change its brand logo. *The log
TOM FORD Unveils Black Orchid Reserve Campaign Starring Tilda Swinton29.8.2025 07:35:00 EEST | Press release
The quest for exceptional rarity. Introducing Tilda Swinton for the new TOM FORD Black Orchid Reserve campaign. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250828507187/en/ “It is a profound honour for me to play a part in the history of TOM FORD’s legendary Black Orchid. Transformation, the blurring of boundaries and the celebration of magical properties have always drawn me close; Black Orchid Reserve is precisely such an enchantment.” — Tilda Swinton A celebrated actor and artist, Swinton is a singular presence known for her fearless artistry and transformative performances. An Academy Award, BAFTA and Golden Lion for Lifetime Achievement winner, Swinton defies conventions with elegance, intellect and a visionary approach to cinema. Her work transcends definition, shaping the culture through work in film, art and performance. TOM FORD creative director Haider Ackermann designed the campaign as a cinematic portrait of r
Novotech Supports Groundbreaking Approval of Anlotinib Combination Therapy for Advanced Soft Tissue Sarcoma28.8.2025 23:15:00 EEST | Press release
Novotech, a globally recognized full-service clinical research organization (CRO), is proud to have partnered with Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (CTTQ Pharma) in achieving a significant regulatory milestone: the approval of Anlotinib Hydrochloride Capsules for a new indication as a first-line treatment for unresectable locally advanced or metastatic soft tissue sarcoma (STS) in combination with chemotherapy. This approval marks the ninth indication for Anlotinib in China and represents the world’s first official approval of an Anlotinib-chemotherapy combination for first-line treatment of advanced or metastatic STS. Previously recommended as a second-line monotherapy by the Chinese Society of Clinical Oncology (CSCO) guidelines, Anlotinib was the only Grade I targeted therapy for STS. This new indication represents a significant advancement for patients who have not previously received systemic treatment, expanding access to more effective and targeted first-line the
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom